Lead Product(s) : PRV-101
Therapeutic Area : Endocrinology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Publication results demonstrates that a preclinical prototype of Provention's polyvalent coxsackievirus B (CVB) vaccine, PRV-101, is well-tolerated, immunogenic and highly protective in relevant animal models.
Product Name : PRV-101
Product Type : Vaccine
Upfront Cash : Inapplicable
May 18, 2020
Lead Product(s) : PRV-101
Therapeutic Area : Endocrinology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MAR002
Therapeutic Area : Endocrinology
Study Phase : IND Enabling
Sponsor : ProBioGen
Deal Size : Undisclosed
Deal Type : Partnership
ProBioGen and Marea Therapeutics Accelerate MAR002 Antibody
Details : The parternship aims to deliver clinical material for MAR002, Marea’s investigational anti-growth hormone receptor (GHR) antibody for the treatment of acromegaly.
Product Name : MAR002
Product Type : Antibody
Upfront Cash : Undisclosed
March 05, 2025
Lead Product(s) : MAR002
Therapeutic Area : Endocrinology
Highest Development Status : IND Enabling
Sponsor : ProBioGen
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Thyroid Cell
Therapeutic Area : Endocrinology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sernova Submits IND for Cell Pouch Bio-Hybrid Organ in Hypothyroidism
Details :
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 03, 2025
Lead Product(s) : Thyroid Cell
Therapeutic Area : Endocrinology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SAB-142
Therapeutic Area : Endocrinology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Bio
Details : SAB-142 is a human alternative to rabbit anti-thymocyte globulin, SAB-142’s mechanism of action is analogous to that of rabbit ATG, which is being clinically validated in the clinical trials for T1D.
Product Name : SAB-142
Product Type : Antibody
Upfront Cash : Inapplicable
May 21, 2024
Lead Product(s) : SAB-142
Therapeutic Area : Endocrinology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SAB-142
Therapeutic Area : Endocrinology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SAB-142 is the first fully-human anti-thymocyte hpAB therapeutic currently being developed for delaying the progression and onset of type 1 diabetes, among other autoimmune indications.
Product Name : SAB-142
Product Type : Antibody
Upfront Cash : Inapplicable
October 19, 2023
Lead Product(s) : SAB-142
Therapeutic Area : Endocrinology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SAB-142
Therapeutic Area : Endocrinology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SAB-142 is the first fully-human anti-thymocyte hpAB therapeutic currently being developed for delaying the progression and onset of type 1 diabetes, among other autoimmune indications.
Product Name : SAB-142
Product Type : Antibody
Upfront Cash : Inapplicable
October 01, 2023
Lead Product(s) : SAB-142
Therapeutic Area : Endocrinology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VX-264
Therapeutic Area : Endocrinology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VX-264 is an investigational cell therapy in which allogeneic human stem cell-derived islets are encapsulated in a channel array device designed to shield the cells from the body’s immune system. It is currently being evaluated for patients with T1D.
Product Name : VX-264
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 03, 2023
Lead Product(s) : VX-264
Therapeutic Area : Endocrinology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MBX 1416
Therapeutic Area : Endocrinology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MBX 1416 is an investigational long-acting GLP-1 receptor antagonist in development as a potential treatment for Post-Bariatric Hypoglycemia. It was designed using the company’s novel, proprietary PEP platform to prevent the occurrence of severe hypogl...
Product Name : MBX 1416
Product Type : Hormone
Upfront Cash : Inapplicable
July 08, 2023
Lead Product(s) : MBX 1416
Therapeutic Area : Endocrinology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BMF-219
Therapeutic Area : Endocrinology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMF-219 is a novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 1 diabetes. The FDA has cleared the initiation of COVALENT-112, a Phase II clinical trial.
Product Name : BMF-219
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 10, 2023
Lead Product(s) : BMF-219
Therapeutic Area : Endocrinology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SAB-142
Therapeutic Area : Endocrinology
Study Phase : IND Enabling
Sponsor : RA Capital Management
Deal Size : $130.0 million
Deal Type : Private Placement
Details : SAB will use the funds to clinically advance SAB-142, a fully-human alternative to rabbit anti-thymocyte globulin (rATG), its lead therapeutic candidate for type 1 diabetes (T1D).
Product Name : SAB-142
Product Type : Antibody
Upfront Cash : Undisclosed
February 10, 2023
Lead Product(s) : SAB-142
Therapeutic Area : Endocrinology
Highest Development Status : IND Enabling
Sponsor : RA Capital Management
Deal Size : $130.0 million
Deal Type : Private Placement